COVID-19

The world wasn’t ready for COVID-19. But if we learn the right lessons, next time next time we’ll do better.

The COVID-19 pandemic exposed weaknesses in pharma supply chains. It’s time to address these.

African vaccine production needs a boost. Here’s how Aspen is working to make that happen.

Driven by the success of COVID-19 vaccines, mRNA products are expanding drug developers’ pipelines.

Medicines Patent Pool has joined forces with over 30 generic manufacturers to help ensure access to anti-COVID-19 medicines for all.

With the FDA still behind on inspections, manufacturers need to uncover their own blindspots.

Our eBook features mRNA vs malaria, vaccines, top tips for mRNA sequencing, and more

That which we call rosaimab by any other name would find regulatory approval and commercial success. Or would it?

As the fires of the American opioid crisis continue to burn, can new painkillers step in?

We explore the potential of mRNA as therapeutics and the challenges associated with analysis and sequencing.